Inmedix UK
Expanding Our Vision

In 2017, Inmedix established its subsidiary, Inmedix UK, Ltd. to conduct clinical research.

Single-Payer System Solutions

In addition to conducting clinical research, Inmedix UK seeks to consider the health economic impact of our approach in a single-payer system.

Within an economy one sixth the size of the Unites States, the cost of autoimmune disease treatment is an exceptional challenge in the UK. Inmedix looks forward to working with our UK colleagues and Inmedix Scientific Advisory Board members, Professors Peter Taylor (Oxford) and Ernest Choy (Cardiff), the National Rheumatoid Arthritis Society (NRAS) and governmental agencies to search for superior and more cost-effective therapies for patients with autoimmune diseases across the pond.